Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Observational × disitamab vedotin × Clear all

Status

Sponsor Class

Study Type

Interventional 37 Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Surveys and Questionnaires 463 Blood Specimen Collection 353 Surgical Procedures, Operative 135 Radiotherapy 121 Interviews as Topic 121 Drug Therapy 109 Observation 101 Magnetic Resonance Spectroscopy 96 Biopsy 93 Specimen Handling 65 Data Collection 64 Neoadjuvant Therapy 59 Immunohistochemistry 57 Magnetic Resonance Imaging 56 Immune Checkpoint Inhibitors 52 Watchful Waiting 46 Bevacizumab 43 Ultrasonography 41 Positron Emission Tomography Computed Tomography 40 Immunotherapy 40 Liquid Biopsy 39 Radiosurgery 37 pembrolizumab 36 Therapeutics 36 Gene Expression Profiling 36 Hematologic Tests 35 Tomography, X-Ray Computed 34 Focus Groups 34 Colonoscopy 33 High-Energy Shock Waves 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05851677 2025-09-17

Disitamab Vedotin (RC48-ADC) in Breast Cancer

RenJi Hospital

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡